Search Results

The IQool System is a thermal regulating system indicated for monitoring and controlling patient temperature.

The IQool™ System is a non-invasive, thermal regulating system that monitors and controls patient temperature within a range of 33°C to 38.5°C (91.4°F to101.3°F).

The IOooL™ System consists of:

• ECU 100 Refrigeration and Control Unit an integrated control system operated via a . touch screen monitor.
• BC COOL a cooling liquid consisting of diluted monopropylene glycol (MPG5). The ● dilution is made by BrainCool AB to optimally serve the IQool™ System. Five liters of BC COOL are delivered with the system.
• Cooling Pads The Cooling Pads are made of non-sterile, biocompatible material and do ● not contain latex. The Cooling Pads are intended for single use only.
• . Stabilization Insulation - The patented stabilization is made of insulating and moisture-absorbent neoprene. It insulates against the ambient environment while counteracting condensation. The elasticity of the stabilization keeps the Cooling Pad in place during treatment and ensures maximum contact between the skin and the surface of the Cooling Pad. The stabilizing insulation is intended for single use only.

Accessories:

• BC Stick a USB flash drive used to save system configurations, specifically prepared to ● communicate with the program of the IQool™ System. The BC stick does not store or capture any user identifying information. It can also be used to save a log file for system troubleshooting or to update the software.
• Filling Pitcher - The filling pitcher should be used to fill or refill the coolant tank. Fill the tank with coolant before or directly after starting to enable start of the system.

The IQool™ System is a thermoregulatory device that monitors and controls patient temperature within a range of 33°C to 38.5°C. The IQool System refrigeration and control unit (ECU 100) pushes a temperature-controlled cooling agent (BC COOL), ranging between 4°C and 40°C, through the Cooling Pads applied to the patient. This results in heat exchange between the BC COOL and the patient. Patient core temperature is monitored and controlled based on the temperature probe (PT1) attached to the system. The IQool™ System maintains a controlled patient temperature during the entire treatment period. The default treatment settings for temperature and time can be changed via the touchscreen monitor. Alarms and notifications are activated if any errors are detected. Temperature graphs for each treatment are shown on the touchscreen display for visual monitoring. After a treatment, a detailed log file can be collected with the memory stick (BC STICK).

This is a 510(k) premarket notification for a medical device called The IQool System, which is a thermal regulating system. The document states that a special 510(k) was submitted for "software changes," implying that the device itself has not fundamentally changed but its software has been updated. The submission aims to demonstrate substantial equivalence to a predicate device (K180375 IQool Warm System).

The provided text does not contain any information about acceptance criteria or a study that proves the device meets specific performance criteria. It primarily focuses on the regulatory submission process, device description, and a claim of substantial equivalence based on "testing summaries" for software changes.

Therefore, I cannot provide a table of acceptance criteria or details regarding a study as requested, because this information is not present in the provided document. The document only mentions that "testing summaries provided document that the changes were verified and that the subject device provides the same temperature management performance and safety as the predicate device," but it does not elaborate on what these tests entailed, their results, or the acceptance criteria used.

Ask a specific question about this device

The Cooral Device is intended to cool the oral mucosa during chemotherapy treatments to reduce the likelihood and severity of chemotherapy induced Oral Mucositis in adult patients.

The Cooral System is an intraoral mouthpiece that cools the oral mucosa using a water coolant which circulates internally through the mouthpiece for patients undergoing chemotherapy treatment to reduce the likelihood and severity of oral mucositis. Oral mucositis is one of the most common, debilitating complications of cancer treatment. The device consists of an energy control unit with a computerized control system to which an intraoral mouthpiece is connected via plastic tubing. Liquid coolant (sterile water) is circulated from the tank through the plastic tubes of the intraoral mouthpiece and is designed to specifically cool the areas where the major arteries enter the oral cavity. The cooling is initiated 30 minutes prior to start of chemotherapy infusion and continues 30 minutes after termination of the infusion time can vary between 15 min to 3 hours based on the half-life of the chemotherapeutics.

The Cooral System pushes temperature-controlled coolant which results in heat exchange between the Cooral System, and the patient's oral mucosa. The coolant temperature is controlled by a thermostat and its temperature probe. The Cooral System maintains a controlled coolant temperature at 8°C during the entire treatment period.

The device is intended to use is intended to reduce the severity and likelihood of oral mucositis in patients undergoing chemotherapy treatment. The device is a system made out of different components.

The device consists of three components:

• 1. Computerized Control System (ECU 200 refrigeration and control unit)
• 2. Plastic tubing connecting the ECU to the mouthpiece
• 3. Intraoral Mouthpiece

The provided text describes the Cooral System, an intraoral cooling device intended to reduce the likelihood and severity of chemotherapy-induced oral mucositis. However, the document does not describe an AI/algorithm-based device and therefore does not contain information typically found in acceptance criteria or study designs for AI/ML medical devices. The study detailed is a clinical trial comparing the Cooral System to ice cooling, focusing on its efficacy and tolerability for preventing oral mucositis.

Therefore, I cannot extract information related to AI/ML specific acceptance criteria, sample sizes for training/test sets, expert adjudication methods, MRMC studies, standalone performance, or ground truth establishment for AI/ML algorithms from the provided text.

Based on the information provided, here's a breakdown of the clinical study conducted for the Cooral System, interpreted in the context of device performance, not AI/ML performance:

Acceptance Criteria (Implied Clinical Performance)

While the document doesn't explicitly list "acceptance criteria" in a table for an AI/ML device, the clinical study aimed to demonstrate the device's efficacy and tolerability. The "results" section implicitly serves as the performance assessment against the study objectives.

Table of Implied "Acceptance Criteria" and Reported Device Performance (Clinical Study Outcomes)

• Cooral Mean Peak OMAS Total Score: 0.988 (N=84)
• Ice Mean Peak OMAS Total Score: 1.239 (N=88)
• Mean Difference: -0.251
• p-value: 0.3518 (Not statistically significant)

Lymphoma Subgroup (Table 3):

• Cooral Mean Peak OMAS Score: 1.769 (N=13)
• Ice Mean Peak OMAS Score: 3.077 (N=13)
• Mean Difference: -1.308
• p-value: 0.0499 (Statistically significant for this subgroup, specifically "a statistically significant, higher percentage of freedom from severe OM which is represented by peak OMAS score of ≥3" - actual reported p=0.047 in text, 0.0499 in Table 3). |
  | Secondary Objective: Tolerability (Discomfort) | Statistically significant reduction in reported discomfort compared to ice. | Full Analysis Set (Table 2):
• Cooral: 4/80 (5.00%) reported discomfort
• Ice: 14/87 (16.09%) reported discomfort
• Odds Ratio: 0.274 (95% CI 0.086-0.873)
• p-value: 0.0285 (Statistically significant) |
  | Safety | Acceptable safety profile, no new or unexpected serious adverse events. | No device-related serious adverse events observed (Table 2, Adverse Events). Adverse events were temporary and transient (e.g., poor fit, rubbing discomfort, difficulties swallowing in ICD group; chills, numbness, teeth hypersensitivity in Ice group). |

Study Details (Clinical Study, Not AI/ML)

1. Sample Size Used for the Test Set and Data Provenance:

   • Sample Size: A total of 183 participants were randomized: 90 to the Cooral Device group and 93 to the Ice group.
   • Data Provenance: The study was conducted in five hospital sites in Sweden. The clinical trial was a prospective, randomized controlled trial.

2. Number of Experts Used to Establish Ground Truth for the Test Set and Qualifications of Those Experts:

   • The "ground truth" for oral mucositis (OM) assessment was established using the Oral Mucositis Assessment Scale (OMAS total).
   • Experts: Dental staff in charge of assessing OM were used. They were blinded to the interventions.
   • Qualifications: The document does not specify the specific qualifications (e.g., years of experience, types of dental professionals) of the dental staff.

3. Adjudication Method for the Test Set:

   • The document states that the dental staff in charge of assessing OM were "blinded" to the interventions. It does not explicitly mention a multi-reader or adjudication process (e.g., 2+1, 3+1) among the dental staff for establishing the OMAS scores per patient. It implies that the scores were collected directly without a formal adjudication for consistency between multiple assessors for the same patient.

4. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done:

   • No. This was a clinical trial comparing a device (Cooral System) to a standard practice (ice cooling) in patients, assessing clinical outcomes (oral mucositis severity, tolerability). It was not an MRMC study comparing human reader performance with and without AI assistance.

5. If a Standalone (Algorithm Only Without Human-in-the-Loop Performance) Was Done:

   • Not applicable. The Cooral System is a physical medical device, not an algorithm. Its performance is assessed in a clinical setting in patients in conjunction with healthcare professionals.

6. The Type of Ground Truth Used:

   • The primary ground truth for efficacy was the Oral Mucositis Assessment Scale (OMAS total), which is a validated assessment scale based on direct clinical observation (ulceration and erythema graded by dental staff).
   • For tolerability, ground truth was established through subjective questionnaires filled out by patients (e.g., Numeric Pain Rating, questionnaire on discomfort/side effects) and daily online diaries.

7. The Sample Size for the Training Set:

   • Not applicable. This is a physical device, not an AI/ML algorithm requiring a training set.

8. How the Ground Truth for the Training Set Was Established:

   • Not applicable. As above, this is not an AI/ML device.

Ask a specific question about this device